PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 4,600 shares, a decline of 14.8% from the May 31st total of 5,400 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 3,400 shares, the days-to-cover ratio is currently 1.4 days.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of PolyPid in a report on Tuesday, June 18th.
Get Our Latest Analysis on PYPD
Institutional Inflows and Outflows
PolyPid Price Performance
Shares of PYPD stock opened at $4.24 on Tuesday. PolyPid has a 12 month low of $3.57 and a 12 month high of $12.30. The stock has a 50 day moving average of $4.44 and a 200-day moving average of $5.12. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.60.
PolyPid (NASDAQ:PYPD – Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($1.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.96) by $0.59. Research analysts predict that PolyPid will post -4.98 EPS for the current year.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
See Also
- Five stocks we like better than PolyPid
- How to Start Investing in Real Estate
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Evaluate a Stock Before BuyingÂ
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Where Do I Find 52-Week Highs and Lows?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.